Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2019

01-11-2019 | Breast Cancer | Original Article

Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls

Authors: Masahiro Manfuku, Tomohiko Nishigami, Akira Mibu, Katsuyoshi Tanaka, Kazufumi Kitagaki, Kazuhiro Sumiyoshi

Published in: Breast Cancer | Issue 6/2019

Login to get access

Abstract

Background

In breast cancer survivors, multiple risk factors for health-related quality of life (HRQoL) and chronic pain, including cancer treatment-related factors, psychosocial factors, and central sensitization (CS), have been suggested; however, there has been no comparative study between breast cancer survivors with and without pain. This study aimed to compare the demographic characteristics, psychological factors, and CS-related symptoms between breast cancer survivors with pain, those without pain, and healthy controls, and to investigate the relationships of these factors with HRQoL.

Methods

We conducted a cross-sectional survey of 218 women, including patients who underwent breast cancer surgery and adjuvant therapy and healthy women.

Results

Patients were divided into the pain group (n = 42), without-pain group (n = 51), and healthy group (n = 47); thus, among breast cancer survivors, 45% reported chronic pain. The proportion of participants who received breast cancer treatments, such as axillary lymph node dissection and chemotherapy, was higher in the pain group than in the without-pain group (p < 0.05). The Central Sensitization Inventory (CSI) and psychosocial factors in the pain group were higher than those in the without-pain group and healthy group (p < 0.01). The CSI and PCS showed larger effect sizes than treatment-related factors. Moreover, HRQoL was significantly correlated with CSI, PCS, Patient Health Questionnaire-2, and Generalized Anxiety Disorder-2 scale (all, p < 0.01). On multiple linear regression analysis, CSI accounted for 43% of the variance in HRQoL.

Conclusions

CS and pain catastrophizing may be more associated with the development and/or maintenance of persistent pain than treatment-related factors.
Literature
1.
Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.CrossRefPubMed
2.
Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMed
3.
Schou BI, Smeby NA, Ottesen S, Warncke T, Schlichting E. Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manag. 2014;48:852–62.CrossRef
4.
Juhl AA, Christiansen P, Damsgaard TE. Persistent pain after breast cancer treatment: a questionnaire-based study on the prevalence, associated treatment variables, and pain type. J Breast Cancer. 2016;19:447–54.CrossRefPubMedPubMedCentral
5.
Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;4:188.
6.
Bosompra K, Ashikaga T, O’Brien PJ, Nelson L, Skelly J. Swelling, numbness, pain, and their relationship to arm function among breast cancer survivors: a disablement process model perspective. Breast J. 2002;8:338–48.CrossRefPubMed
7.
Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life. Breast Cancer Res Treat. 2018;167:157–69.CrossRefPubMed
8.
Stubblefield MD, Keole N. Upper body pain and functional disorders in patients with breast cancer. PM&R Funct Rehabil. 2014;6:170–83.CrossRef
9.
Nijs J, Leysen L, Adriaenssens N, Aguilar Ferrándiz ME, Devoogdt N, Tassenoy A, et al. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol. 2016;55:659–63.CrossRefPubMed
10.
Chapman CR, Vierck CJ. The transition of acute postoperative pain to chronic pain: an integrative overview of research on mechanisms. J Pain. 2017;18:359.CrossRefPubMed
11.
Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-las-Peñas C, Del-Moral-Ávila R, Menjón-Beltrán S, Arroyo-Morales M. Widespread mechanical pain hypersensitivity as a sign of central sensitization after breast cancer surgery: comparison between mastectomy and lumpectomy. Pain Med. 2011;12:72–8.CrossRefPubMed
12.
Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las-Peñas C, Del-Moral-Ávila R, Arendt-Nielsen L, Arroyo-Morales M. Myofascial trigger points in neck and shoulder muscles and widespread pressure pain hypersensitivity in patients with postmastectomy pain: evidence of peripheral and central sensitization. Clin J Pain. 2010;26:798–806.CrossRefPubMed
13.
Leysen L, Adriaenssens N, Nijs J, Pas R, Bilterys T, Vermeir S, et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain? Pain Pract. 2019;19:183–95.CrossRefPubMed
14.
15.
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–15.CrossRefPubMed
16.
Edwards RR, Mensing G, Cahalan C, Greenbaum S, Narang S, Belfer I, et al. Alteration in pain modulation in women with persistent pain after lumpectomy: influence of catastrophizing. J Pain Symptom Manag. 2013;46:30–42.CrossRef
17.
Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the Central Sensitization Inventory. Pain Pract. 2012;12:276–85.CrossRefPubMed
18.
Kregel J, Schumacher C, Dolphens M, Malfliet A, Goubert D, Lenoir D, et al. Convergent validity of the dutch Central Sensitization Inventory: associations with psychophysical pain measures, quality of life, disability, and pain cognitions in patients with chronic spinal pain. Pain Pract. 2018;18:777–87.CrossRefPubMed
19.
Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the Central Sensitization Inventory: a systematic review. Pain Pract. 2018;18:544–54.CrossRefPubMed
20.
Caumo W, Antunes LC, Elkfury JL, Herbstrith EG, Busanello Sipmann R, Souza A, et al. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017;10:2109–22.CrossRefPubMedPubMedCentral
21.
Tanaka K, Nishigami T, Mibu A, Manfuku M, Yono S, Shinohara Y, et al. Validation of the Japanese version of the Central Sensitization Inventory in patients with musculoskeletal disorders. PLoS One. 2017;12:e0188719.CrossRefPubMedPubMedCentral
22.
Coronado RA, George SZ. The Central Sensitization Inventory and Pain Sensitivity Questionnaire: an exploration of construct validity and associations with widespread pain sensitivity among individuals with shoulder pain. Musculoskelet Sci Pract. 2018;36:61–7.CrossRefPubMedPubMedCentral
23.
De Groef A, Meeus M, De Vrieze T, Vos L, Van Kampen M, Geraerts I, et al. Unraveling self-reported signs of central sensitization in breast cancer survivors with upper limb pain: prevalence rate and contributing factors. Pain Physician. 2018;21:E247–56.CrossRefPubMed
24.
Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early-stage breast cancer. Breast Dis. 2004;21:55–64.CrossRefPubMed
25.
Yu J, Son WS, Lee SB, Chung IY, Son BH, Ahn SH, et al. Uneven recovery patterns of compromised health-related quality of life (EQ-5D-3 L) domains for breast Cancer survivors: a comparative study. Health Qual Life Outcomes. 2018;16:143.CrossRefPubMedPubMedCentral
26.
So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. Eur J Oncol Nurs. 2010;14:17–22.CrossRefPubMed
27.
Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003–7.PubMedPubMedCentral
28.
Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory—BPI-J. J Pain Symptom Manag. 1998;16:364–73.CrossRef
29.
Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the Central Sensitization Inventory. Pain Pract. 2017;17:166–75.CrossRefPubMed
30.
Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.CrossRefPubMed
31.
Sullivan M, Bishop S, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7:524–32.CrossRef
32.
Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348–53.CrossRefPubMedPubMedCentral
33.
Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31.CrossRefPubMed
34.
Vahdaninia M, Omidvari S, Montazeri A. What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol. 2010;45:355–61.CrossRefPubMed
35.
Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer survivors. J Clin Oncol. 2013;31:3540–8.CrossRefPubMed
36.
Andersen LN, Kohberg M, Juul-Kristensen B, Herborg LG, Søgaard K, Roessler KK. Psychosocial aspects of everyday life with chronic musculoskeletal pain: a systematic review. Scand J Pain. 2014;5:131–48.CrossRefPubMed
37.
Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst. 2003;95:263–81.CrossRefPubMed
38.
Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a predictor of worse quality of life measures and increased length of stay following spinal fusion. World Neurosurg. 2017;104:594–600.CrossRefPubMed
39.
Wong WS, Lam HM, Chow YF, Chen PP, Lim HS, Wong S, et al. The effects of anxiety sensitivity, pain hypervigilance, and pain catastrophizing on quality of life outcomes of patients with chronic pain: a preliminary, cross-sectional analysis. Qual Life Res. 2014;23:2333–41.CrossRefPubMed
40.
van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology. 2008;17:1137–45.CrossRefPubMed
Metadata
Title
Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls
Authors
Masahiro Manfuku
Tomohiko Nishigami
Akira Mibu
Katsuyoshi Tanaka
Kazufumi Kitagaki
Kazuhiro Sumiyoshi
Publication date
01-11-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00979-y

Other articles of this Issue 6/2019

Breast Cancer 6/2019 Go to the issue

Case Report

Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers

Original Article

Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes

Original Article

Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome

Letter to the Editor

Mean platelet volume may not be an independent prognostic factor in breast cancer patients with type 2 diabetes mellitus

Original Article

RETRACTED ARTICLE: Association of insulin-like growth factor 1 receptor and estrogen receptor with pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer

Original Article

Simultaneous comparison between strain and shear wave elastography of breast masses for the differentiation of benign and malignant lesions by qualitative and quantitative assessments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits